Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.32 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL18954261 | 0.97 | PTK2 (0.37) | PTK2CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4900924 | 0.78 | PTK2 (0.48) | PTK2 | |
| SCHEMBL4899113 | 0.77 | TSHR (0.42) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4903990 | 0.77 | CHRNA7 (0.38) | CHRNA7BCHEACHECHKA | |
| SCHEMBL7263081 | 0.77 | CHRNA7 (0.38) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1666073 | 0.74 | CHRNA7 (0.36) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL12036494 | 0.74 | CHRNA7 (0.36) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Bromide SCHEMBL7629729 | 0.74 | CHRNA7 (0.36) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL14651460 | 0.72 | BCHE (0.35) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Water SCHEMBL8053367 | 0.72 | CHRNA7 (0.35) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386484-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2017099823-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017099823-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20150112051-A1 | CONSTRUCTION OF CELL PENETRATING NUCLEIC ACIDS | Panzner, Steffen | 2015-04-23 | — | — | US | disclosed |
| US-8957191-B2 | Nucleic acid comprising zwitterionic nucleotides | STEFFEN PANZNER (DE) | 2015-02-17 | — | — | US | disclosed |
| EP-1867667-B1 | Method for manufacturing stabilized polyacetal resin | POLYPLASTICS CO (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20110137019-A1 | NUCLEIC ACID COMPRISING ZWITTERIONIC NUCLEOTIDES | BIONTECH PROTEIN THERAPEUTICS GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
| US-20080271381-A1 | Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin | POLYPLASTICS CO., LTD (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1867667-A1 | Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin | Polyplastics Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20070167408-A1 | NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | ZENTARIS GMBH (DE) | 2007-07-19 | — | — | US | disclosed |
| WO-2007071658-A2 | ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | ÆTERNA ZENTARIS GMBH (DE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167408-A1 | NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | PHOSPHO1, PTDSS1, PTDSS2 | PTK2 2081/4885CHRNA7 4836/4885CHRNB2 4862/4885 |
| US-20110137019-A1 | NUCLEIC ACID COMPRISING ZWITTERIONIC NUCLEOTIDES | NSUN3, NCL, NUDT1 | PTK2 4636/4885CHRNA7 2234/4885CHRNB2 3385/4885 |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | PTK2 2670/4885CHRNA7 4162/4885CHRNB2 3362/4885 |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | PTK2 2670/4885CHRNA7 4162/4885CHRNB2 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.